Bifogade filer
PDF
Kurs
-4,87%
Likviditet
4,69 MSEK
Kalender
| Est. tid* | ||
| 2026-05-08 | 07:00 | Bokslutskommuniké 2026 |
| 2026-02-03 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2025-11-05 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2025-08-22 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2025-08-21 | - | Årsstämma |
| 2025-08-08 | - | Kvartalsrapport 2026-Q1 |
| 2025-05-08 | - | Bokslutskommuniké 2025 |
| 2025-02-05 | - | Kvartalsrapport 2025-Q3 |
| 2024-11-06 | - | Kvartalsrapport 2025-Q2 |
| 2024-08-20 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2024-08-19 | - | Årsstämma |
| 2024-08-08 | - | Kvartalsrapport 2025-Q1 |
| 2024-05-14 | - | Bokslutskommuniké 2024 |
| 2024-02-14 | - | Kvartalsrapport 2024-Q3 |
| 2023-11-17 | - | Kvartalsrapport 2024-Q2 |
| 2023-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2023-08-17 | - | Årsstämma |
| 2023-08-16 | - | Kvartalsrapport 2024-Q1 |
| 2023-05-11 | - | Bokslutskommuniké 2023 |
| 2023-02-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-02-13 | - | Kvartalsrapport 2023-Q3 |
| 2022-11-11 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-26 | - | Extra Bolagsstämma 2022 |
| 2022-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2022-08-17 | - | Årsstämma |
| 2022-08-16 | - | Kvartalsrapport 2023-Q1 |
| 2022-05-13 | - | Bokslutskommuniké 2022 |
| 2022-02-16 | - | Kvartalsrapport 2022-Q3 |
| 2021-11-11 | - | Kvartalsrapport 2022-Q2 |
| 2021-08-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2021-08-18 | - | Årsstämma |
| 2021-08-18 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-06 | - | Bokslutskommuniké 2021 |
| 2021-02-18 | - | Kvartalsrapport 2021-Q3 |
| 2020-11-06 | - | Kvartalsrapport 2021-Q2 |
| 2020-08-28 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2020-08-27 | - | Årsstämma |
| 2020-08-27 | - | Kvartalsrapport 2021-Q1 |
| 2020-05-04 | - | Bokslutskommuniké 2020 |
| 2020-02-05 | - | Kvartalsrapport 2020-Q3 |
| 2019-11-11 | - | Kvartalsrapport 2020-Q2 |
| 2019-08-23 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2019-08-22 | - | Årsstämma |
| 2019-08-22 | - | Kvartalsrapport 2020-Q1 |
| 2018-08-22 | - | Årsstämma |
| 2018-05-24 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2018-05-23 | - | Bokslutskommuniké 2018 |
| 2017-10-24 | - | Kvartalsrapport 2018-Q3 |
| 2017-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2017-05-16 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2017-05-15 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2017-02-08 | - | Bokslutskommuniké 2017 |
| 2016-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2016-08-09 | - | Kvartalsrapport 2017-Q2 |
| 2016-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2016-05-13 | - | Årsstämma |
| 2016-05-13 | - | Kvartalsrapport 2017-Q1 |
| 2016-02-20 | - | Bokslutskommuniké 2016 |
| 2016-02-16 | - | Bokslutskommuniké 2016 |
| 2015-11-11 | - | Kvartalsrapport 2016-Q3 |
| 2015-10-09 | - | Extra Bolagsstämma 2016 |
| 2015-08-05 | - | Kvartalsrapport 2016-Q2 |
| 2015-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2015-05-18 | - | Årsstämma |
| 2015-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2015-02-06 | - | Bokslutskommuniké 2015 |
| 2014-11-10 | - | Kvartalsrapport 2015-Q3 |
| 2014-08-13 | - | Extra Bolagsstämma 2015 |
| 2014-08-11 | - | Kvartalsrapport 2015-Q2 |
| 2014-05-13 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2014-05-12 | - | Årsstämma |
| 2014-05-12 | - | Kvartalsrapport 2015-Q1 |
| 2014-02-07 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position. Alexander has been active in EQL Pharma since 2016 and will remain in his role until the end of December 2025 and ensure a stable handover.
- We would like to thank Alexander for his efforts over all these years, especially within the company's commercial strategies where he has worked to ensure that the portfolio of pharmaceutical products reaches its full potential in the geographical markets where EQL Pharma operates, both Nordic and European. Alexander has been a central part of our journey.
"I would like to thank Alexander for his invaluable contribution over many years with us and all the knowledge he has contributed. We wish him all the best in the future," says Axel Schörling, CEO of EQL Pharma.
The process to recruit a new CCO is in its final stages, and the Company will provide more information as soon as possible, in consultation with the individual's current employer.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com